LOUISVILLE, Ky., July 25, 2014 /PRNewswire/ -- Neuronetrix will be reporting at AAIC 2014 that neuro-electrophysiological measures recorded using the company's COGNISION System can be used to differentiate patients with mild Alzheimer's disease from healthy controls. Previous scientific studies have demonstrated the discriminatory power of these measures in highly controlled research environments. Neuronetrix's study demonstrated that these measures can be reliably recorded and analyzed in real world clinical settings.
The study included over 200 subjects from seven clinical sites across the US. All tests were administered by non-expert clinical staff and the data was automatically analyzed by the COGNISION System. The results include an exhaustive analysis of the complex electrophysiological features and show their statistical correlation to Alzheimer's disease.
In addition to their clinical utility, these biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of drug effects.
"This study has confirmed COGNISION System's ability to bridge the gap between interesting scientific findings and practical clinical applications," said Marco Cecchi, PhD, Neuronetrix's Director of Research and Clinical Affairs. "Clinicians and pharmaceutical companies now have access to reliable biomarkers of Alzheimer's disease in real world clinical settings."
Study results will be presented at Alzheimer's Association International Conference (AAIC) in Copenhagen, Denmark from July 12-17, 2014, during a scientific oral session and at an ISTAART event.
The COGNISION System is a proprietary neuro-electrophysiological device which provides objective assessments of cognitive function. COGNISION implements powerful and validated scientific methods in a practical, cost effective, and easy to use design.
Neuronetrix, developer of the COGNISION System, is a leading neurotech company focused on providing physicians and scientists with accurate and meaningful information about brain processing. This information is critical in the understanding of complex brain function, diagnosis of cognitive disorders, and evaluating the effects of pro-cognitive therapies.
Information about Neuronetrix is available at http://www.neuronetrix.com or by contacting Daniel Lawson at email@example.com, or (502) 561-9040, x7003.
1044 E. Chestnut St.
Louisville KY 40204
(502) 561-9040, x7003